full issue - Association of Biotechnology and Pharmacy

Current Trends in Biotechnology and Pharmacy
Vol. 5 (3) 1251-1272 July 2011, ISSN 0973-8916 (Print), 2230-7303 (Online)
1269
endothelin receptor antagonist:
Implications for endothelin physiology. J
Cardiovasc Pharmacol., 22: S377-S379.
42. Breu, V., Loffler, B.M. and Clozel, M.
(1993). In vitro characterization of Ro 46-
2005, a novel synthetic non-peptide
endothelin antagonist of ET A
and ET B
receptors. FEBS Lett., 334: 210-214.
43. Chong, C.C. (2009). Ambrisentan: A new,
nonsulphonamide, selective endothelin
receptor antagonist for the treatment of
pulmonary arterial hypertension. Current
Treatment of Pulmonary Vascular Diseases,
1: 31-33.
44. Cao, S., Wang, L.C., Kwansa, H., Roman,
R.J., Harder, D.R. and Koehler, R.C.
(2009). Endothelin rather than 20-HETE
contributes to loss of pial arteriolar dilation
during focal cerebral ischemia with and
without polymeric hemoglobin transfusion.
Am J Physiol Regul Integr Comp Physiol.,
296: R1412-1418.
45. Clozel, M. (2000). Endothelin receptor
antagonists: current status and perspectives.
J Cardiovasc Pharmacol., 35: S65-68.
46. Wellings, R.P., Warner, T.D.,
Thiemermann, C., Cristol, J.P., Corder, R.
and Vane, J.R. (1993). Vasoconstriction in
the rat kidney induced by endothelin-1 is
blocked by PD 145065. J Cardiovasc
Pharmacol., 22: S103-106.
47. Dobrowolski, L., Endlich, K., Sadowski,
J. and Steinhausen, M. (1997).
Cardiovascular and renal effects of
endothelin receptor blockade with PD
145065 and interaction with urodilatin.
Acta Physiol Scand., 159: 7-13.
48. Cardell, L.O., Uddman, R. and Edvinsson,
L. (1993). A novel ET A
-receptor antagonist,
FR 139317, inhibits endothelin-induced
contractions of guinea-pig pulmonary
arteries, but not trachea. Br J Pharmacol.,
108: 448-452.
49. Wu-Wong, J.R. (2002). S-0139 (Shionogi).
Curr Opin Investig Drugs, 3: 1051-1056.
50. Opgenorth, T.J., Adler, A.L., Calzadilla,
S.V., Chiou, W.J., Dayton, B.D., Dixon,
D.B., Gehrke, L.J., Hernandez, L.,
Magnuson, S.R., Marsh, K.C., Novosad,
E.I., Von Geldern, T.W., Wessale, J.L.,
Winn, M. and Wu-Wong, J.R. (1996).
Pharmacological characterization of A-
127722: an orally active and highly potent
ET A
-selective receptor antagonist. J
Pharmacol Exp Ther., 276: 473-481.
51. Krause, S.M., Walsh, T.F., Greenlee, W.J.,
Ranaei, R., Williams, D.L. and Kivlighn,
S.D. (1997). Renal protection by a dual
ET A
/ET B
endothelin antagonist, L-754,142,
after aortic cross-clamping in the dog. J Am
Soc Nephrol., 8: 1061-1071.
52. Enseleit, F., Luscher, T.F. and Ruschitzka,
F. (2008). Darusentan: a new perspective
for treatment of resistant hypertension
Expert Opin Investig Drugs, 17: 1255-
1263.
53. Krum, H., Viskoper, R.J., Lacourciere, Y.,
Budde, M.and Charlon, V. (1998). The
effect of an endothelin-receptor antagonist,
bosentan, on blood pressure in patients with
essential hypertension. Bosentan
Hypertension Investigators. N Engl J Med.,
338: 784-790.
54. Dwyer, N. and Kilpatrick, D. (2011).
Bosentan for the treatment of adult
pulmonary hypertension. Future Cardiol.,
7: 19-37.
55. Dingemanse, J. and van Giersbergen,
P.L.M. (2004). Clinical pharmacology of
Catherina Caballero-George